NCCN Guidelines for Patients® | Esophageal Cancer - page 56

56
NCCN Guidelines for Patients
®
: Esophageal Cancer
Version 1.2013
Part 5: Squamous cell carcinomas
Second-line regimens
Preferred
Docetaxel
Paclitaxel
Irinotecan
Other
Irinotecan and cisplatin
Irinotecan and fluoropyrimidine (5-FU or capecitabine)
Irinotecan and docetaxel
Alternative regimens
Gemcitabine, 5-FU, and leucovorin
Pegylated liposomal doxorubicin, cisplatin, and 5-FU
Mitomycin and irinotecan
Mitomycin, cisplatin, and 5-FU
Mitomycin and 5-FU
Etoposide
Erlotinib
1...,46,47,48,49,50,51,52,53,54,55 57,58,59,60,61,62,63,64,65,66,...100
Powered by FlippingBook